Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 3
2007 2
2008 3
2009 4
2011 2
2012 6
2013 7
2014 3
2015 2
2016 5
2017 5
2018 4
2019 1
2020 5
2021 12
2022 13
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Nicosia L, Spencer GJ, Brooks N, Amaral FMR, Basma NJ, Chadwick JA, Revell B, Wingelhofer B, Maiques-Diaz A, Sinclair O, Camera F, Ciceri F, Wiseman DH, Pegg N, West W, Knurowski T, Frese K, Clegg K, Campbell VL, Cavet J, Copland M, Searle E, Somervaille TCP. Nicosia L, et al. Among authors: copland m. Cancer Cell. 2023 Dec 11;41(12):2136-2153.e13. doi: 10.1016/j.ccell.2023.11.001. Epub 2023 Nov 22. Cancer Cell. 2023. PMID: 37995682 Free article.
Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells.
Rattigan KM, Brabcova Z, Sarnello D, Zarou MM, Roy K, Kwan R, de Beauchamp L, Dawson A, Ianniciello A, Khalaf A, Kalkman ER, Scott MT, Dunn K, Sumpton D, Michie AM, Copland M, Tardito S, Gottlieb E, Vignir Helgason G. Rattigan KM, et al. Among authors: copland m. Nat Commun. 2023 Aug 17;14(1):4634. doi: 10.1038/s41467-023-40222-z. Nat Commun. 2023. PMID: 37591854 Free PMC article.
Targeting BCR-ABL1-positive leukaemias: a review article.
Leak S, Horne GA, Copland M. Leak S, et al. Among authors: copland m. Camb Prism Precis Med. 2023 Mar 6;1:e21. doi: 10.1017/pcm.2023.9. eCollection 2023. Camb Prism Precis Med. 2023. PMID: 38550948 Free PMC article. Review.
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.
Fernando F, Innes AJ, Claudiani S, Pryce A, Hayden C, Byrne J, Gallipoli P, Copland M, Apperley JF, Milojkovic D. Fernando F, et al. Among authors: copland m. Bone Marrow Transplant. 2023 Jul;58(7):826-828. doi: 10.1038/s41409-023-01975-9. Epub 2023 Apr 4. Bone Marrow Transplant. 2023. PMID: 37015970 No abstract available.
The application of BH3 mimetics in myeloid leukemias.
Parry N, Wheadon H, Copland M. Parry N, et al. Among authors: copland m. Cell Death Dis. 2021 Feb 26;12(2):222. doi: 10.1038/s41419-021-03500-6. Cell Death Dis. 2021. PMID: 33637708 Free PMC article. Review.
Novel drug therapies in myeloid leukemia.
Horne GA, Kinstrie R, Copland M. Horne GA, et al. Among authors: copland m. Pharm Pat Anal. 2015;4(3):187-205. doi: 10.4155/ppa.15.3. Pharm Pat Anal. 2015. PMID: 26030080 Free article. Review.
Targeting hedgehog in hematologic malignancy.
Irvine DA, Copland M. Irvine DA, et al. Among authors: copland m. Blood. 2012 Mar 8;119(10):2196-204. doi: 10.1182/blood-2011-10-383752. Epub 2012 Jan 5. Blood. 2012. PMID: 22223823 Free article. Review.
85 results